|Aegis Capital Corp.|
|810 Seventh Avenue, 18 th Floor|
|New York, New York 10019|
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.